Research programme: protein therapeutics - Allgenesis Biotherapeutics

Drug Profile

Research programme: protein therapeutics - Allgenesis Biotherapeutics

Alternative Names: AG 73305

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allgenesis Biotherapeutics
  • Class Disintegrins; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetic macular oedema; Eye-Disorders

Most Recent Events

  • 01 Aug 2017 Early research in Diabetic macular oedema in Taiwan before August 2017 (Allgenesis Biotherapeutics pipeline, August 2017)
  • 17 Mar 2017 Early research in Eye disorders in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top